Editorial: Has MetALD met the presumption?
- PMID: 38757852
- DOI: 10.1111/apt.18034
Editorial: Has MetALD met the presumption?
Comment in
-
Editorial: Has MetALD met the presumption? Authors' reply.Aliment Pharmacol Ther. 2024 Jul;60(1):99-100. doi: 10.1111/apt.18047. Epub 2024 May 17. Aliment Pharmacol Ther. 2024. PMID: 38757828 No abstract available.
Comment on
-
Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality.Aliment Pharmacol Ther. 2024 Jul;60(1):61-69. doi: 10.1111/apt.18015. Epub 2024 Apr 25. Aliment Pharmacol Ther. 2024. PMID: 38664876
References
REFERENCES
-
- Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multi‐society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966–1986. https://doi.org/10.1097/HEP.0000000000000520
-
- Hagström H, Vessby J, Ekstedt M, Shang Y. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J Hepatol. 2024;80:e51–e91.
-
- Rinella ME, Neuschwander‐Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797–1835.
-
- Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero‐Gomez M, et al. A new definition for metabolic dysfunction‐associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202–209.
-
- Kim D, Wijarnpreecha K, Cholankeril G, Ahmed A. Metabolic dysfunction‐associated steatotic liver disease and all‐cause/cause‐specific mortality among adults in the United States. J Hepatol. 2023;80:e79–e81.
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous